אקטיק 200 מקג
abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
אקטיק 600 מקג
abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 600 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
אקטיק 1200 מקג
abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 1200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
איקסל 25 מג
perrigo israel agencies ltd - milnacipran hydrochloride - קפסולות - milnacipran hydrochloride 25 mg - milnacipran - milnacipran - treatment of major (i.e. all characteristics) depressive episodes in adults over 18 years old.
פוסטר 1006
kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - תמיסה לשאיפה - formoterol fumarate dihydrate 6 mcg/dose; beclometasone dipropionate anhydrous 100 mcg/dose - formoterol and beclometasone - beclometasone - foster is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.
פלוטיפורם 505
rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - תרחיף בלחץ לשאיפה - fluticasone propionate 0.05 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting ?2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting ?2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting ?2 agonist.
פלוטיפורם 1255
rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - תרחיף בלחץ לשאיפה - fluticasone propionate 0.125 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting ?2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting ?2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting ?2 agonist.
פלוטיפורם 25010
rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - תרחיף בלחץ לשאיפה - fluticasone propionate 0.25 mg/dose; formoterol fumarate dihydrate 0.01 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting ?2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting ?2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting ?2 agonist.
סימביקורט טורבוהלר 804.5 מקגמנה
astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 80 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - symbicort turbuhaler is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequaterly controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. - or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. note: symbicort turbuhaler 80/4.5 mcg/dose is not appropriate in patients with severe asthma.
סימביקורט טורבוהלר 1604.5 מקגמנה
astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 160 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - asthma symbicort turbuhaler is indicated in the regular treatment of asthma in adults and adolescents age 12 years and above where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. or - patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilators.